All Stories

  1. Randomized Controlled Clinical Trial of Allogeneic Mesenchymal Stromal Cell Infusion in Diabetic Kidney Disease
  2. Response to the Letter to the Editor Entitled “A Missing Genomic Dimension: The Small but Central Mitochondrial Genome in Diabetic Kidney Disease Genetics”
  3. Using a generative co-design framework to adapt an exercise intervention as part of a multimodal intervention for patients’ receiving haemodialysis with or at risk of renal cachexia
  4. Anti-inflammatory effects and safety of omega-3 fatty acids in haemodialysis: A systematic review and meta-analysis
  5. Multi-modal integrated intervention combining exercise, anti-inflammatory, and dietary advice (MMIEAD) for adults with kidney cachexia: protocol for a mixed-methods feasibility cluster randomised controlled trial and process evaluation
  6. Exploring Telomere Association in Donor–Recipient Pairs: Implications for Kidney Graft Longevity
  7. Blood DNA methylation markers are associated with diabetic kidney disease progression in type 1 diabetes
  8. Variation in Attitudes to Native Kidney Biopsy Practice in the United States
  9. Immune cell subsets in young kidney transplant recipients: Mechanistic and clinical perspectives
  10. Exome-Wide Analysis Identifies a Rare EXD3 Missense Variant Associated With Diabetic Kidney Disease
  11. The Association of Socioeconomic Status on Kidney Transplant Access and Outcomes: Cohort Studies of England and Northern Ireland
  12. Low circulating miR-190a-5p predicts progression of chronic kidney disease
  13. Large Language Models’ Clinical Decision-Making on When to Perform a Kidney Biopsy: Comparative Study
  14. Duke activity status index is not predictive of outcomes after kidney transplantation: a retrospective observational study
  15. Effects of empagliflozin on quality of life and healthcare use and costs in chronic kidney disease: a health economic analysis of the EMPA-KIDNEY trial
  16. James Frederick Douglas
  17. Genome-Wide Association Study of Quantitative Kidney Function in 52,531 Individuals with Diabetes Identifies Five Diabetes-Specific Loci
  18. Can large language models’ clinical decision-making match human consensus on when to perform a kidney biopsy? (Preprint)
  19. Donor and Recipient Polygenic Risk Scores Influence Kidney Transplant Function
  20. Polygenic risk scores for eGFR are associated with age at kidney failure
  21. Long-Term Effects of Empagliflozin in Patients with Chronic Kidney Disease
  22. Systematic review of the application of the Kidney Failure Risk Equation and Oxford classification in estimating prognosis in IgA Nephropathy
  23. Non-adherence to immunosuppressive medications in kidney transplant recipients- a systematic scoping review
  24. An International Study of Variation in Attitudes to Kidney Biopsy Practice
  25. The lived experience of renal cachexia: An interpretive phenomenological analysis
  26. Blood methylation biomarkers are associated with diabetic kidney disease progression in type 1 diabetes
  27. Systematic review of the application of the Kidney Failure Equation and Oxford classification in estimating prognosis in IgA Nephropathy
  28. A Novel Role for FERM Domain-Containing Protein 3 in CKD
  29. Does Live Donor and Preemptive Kidney Transplantation Reduce the Impact of Socioeconomic Deprivation on Graft Outcome?
  30. Nonadherence to Immunosuppressive Medications in Kidney Transplant Recipients: A Systematic Scoping Review
  31. ‘Was my kidney biopsy worth it?’–A qualitative phenomenological study of patient experiences and perceived barriers to kidney biopsy
  32. Mitochondrial related variants associated with cardiovascular traits
  33. Frailty, Multimorbidity, and Polypharmacy
  34. Genetic variants affecting mitochondrial function provide further insights for kidney disease
  35. Donor genetic burden for cerebrovascular risk and kidney transplant outcome
  36. Shared genetic features between lymphoma pathogenesis and oestrogen levels
  37. Protocol for a systematic review of the application of the kidney failure risk equation and Oxford classification in estimating prognosis in IgA nephropathy
  38. Genetic and Epigenetic Associations with Post-Transplant Diabetes Mellitus
  39. Latest advances in frailty in kidney transplantation: A narrative review
  40. Low circulating miR-190a-5p predicts progression of chronic kidney disease.
  41. Striking fear into students’ hearts: Unforeseen consequences of prescribing education
  42. Protocol for a Systematic review of the application of the Kidney Failure Risk Equation and Oxford classification in estimating prognosis in IgA Nephropathy
  43. Proteomic analysis investigating kidney transplantation outcomes- a scoping review
  44. Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM)
  45. Albuminuria-Related Genetic Biomarkers: Replication and Predictive Evaluation in Individuals with and without Diabetes from the UK Biobank
  46. #3022 REDUCED TUBULAR MIR-190A-5P: A NOVEL BIOMARKER FOR STRATIFICATION OF PATIENTS WITH CHRONIC KIDNEY DISEASE
  47. Differential Methylation of Telomere-Related Genes Is Associated with Kidney Disease in Individuals with Type 1 Diabetes
  48. A genome-wide association study identifies a possible role for cannabinoid signalling in the pathogenesis of diabetic kidney disease
  49. Harnessing Genomic Analysis to Explore the Role of Telomeres in the Pathogenesis and Progression of Diabetic Kidney Disease
  50. Longitudinal Epigenome-Wide Analysis of Kidney Transplant Recipients Pretransplant and Posttransplant
  51. Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy
  52. Empagliflozin in Patients with Chronic Kidney Disease
  53. Early clinical and economic outcomes of expanded criteria living kidney donors in the United States
  54. Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease
  55. Developing an Evidence and Theory Based Multimodal Integrative Intervention for the Management of Renal Cachexia: A Theory of Change
  56. Mesenchymal stromal cell therapy compared to SGLT2-inhibitors and usual care in treating diabetic kidney disease: A cost-effectiveness analysis
  57. Exploring the lived experience of renal cachexia for individuals with end-stage renal disease and the interrelated experience of their carers: Study protocol
  58. An Analysis of Vascular Access Thrombosis Events From the Proactive IV irOn Therapy in hemodiALysis Patients Trial
  59. Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease
  60. Harnessing the Full Potential of Multi-Omic Analyses to Advance the Study and Treatment of Chronic Kidney Disease
  61. Dialysis, Distress, and Difficult Conversations: Living with a Kidney Transplant
  62. Clinical features and predictive biomarkers for bladder cancer in patients with type 2 diabetes presenting with haematuria
  63. Polycystic Kidney Disease
  64. Stroke in Hemodialysis Patients Randomized to Different Intravenous Iron Strategies: A Prespecified Analysis from the PIVOTAL Trial
  65. Experiences of renal healthcare practitioners during the COVID-19 pandemic: a multi-methods approach
  66. 57 th EASD Annual Meeting of the European Association for the Study of Diabetes
  67. Genome-wide meta-analysis and omics integration identifies novel genes associated with diabetic kidney disease
  68. Retinal microvascular parameters are not associated with diabetes in the Northern Ireland Cohort for the Longitudinal Study of Ageing
  69. Association of renal impairment with cognitive dysfunction in the Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA)
  70. Dietary patterns associated with renal impairment in the Northern Ireland Cohort for the Longitudinal Study of Ageing (NICOLA)
  71. Assessment of differentially methylated loci in individuals with end-stage kidney disease attributed to diabetic kidney disease: an exploratory study
  72. The effects of vitamin E supplementation on malondialdehyde as a biomarker of oxidative stress in haemodialysis patients: a systematic review and meta-analysis
  73. Retinal microvascular parameters are not significantly associated with mild cognitive impairment in the Northern Ireland Cohort for the Longitudinal Study of Ageing
  74. A Critical Review of Multimodal Interventions for Cachexia
  75. A systematic review and participant-level meta-analysis found little association of retinal microvascular caliber with reduced kidney function
  76. Erratum
  77. Investigation of associations between retinal microvascular parameters and albuminuria in UK Biobank: a cross-sectional case-control study
  78. Association of reduced retinal arteriolar tortuosity with depression in older participants from the Northern Ireland Cohort for the Longitudinal Study of Ageing
  79. Variation in retinal microvascular parameters is associated with mild cognitive impairment and Alzheimer’s disease
  80. Nurse-led advance care planning with older people who have end-stage kidney disease: feasibility of a deferred entry randomised controlled trial incorporating an economic evaluation and mixed methods process evaluation (ACReDiT)
  81. Using a generic definition of cachexia in patients with kidney disease receiving haemodialysis: a longitudinal (pilot) study
  82. DNA Methylation Associated With Diabetic Kidney Disease in Blood-Derived DNA
  83. The role of motivational and legal contexts in understanding support for tissue donation across 27 European countries
  84. Prospective payment system and racial/ethnic disparities: a national retrospective observational study in anaemia complication among end-stage renal disease patients in the US
  85. Abstracts
  86. Quality of life in advanced renal disease managed either by haemodialysis or conservative care in older patients
  87. Association of retinal venular tortuosity with impaired renal function in the Northern Ireland Cohort for the Longitudinal Study of Ageing
  88. Assessment of differentially methylated loci in individuals with end-stage kidney disease attributed to diabetic kidney disease
  89. The Potential of Albuminuria as a Biomarker of Diabetic Complications
  90. Estimating the Prevalence of Muscle Wasting, Weakness, and Sarcopenia in Hemodialysis Patients
  91. Understanding the holistic experiences of living with a kidney transplant: an interpretative phenomenological study (protocol)
  92. Utility of Phase Angle to Identify Cachexia and Assess Mortality in End-Stage Renal Disease
  93. Hyperamylasemia Post Living Donor Nephrectomy Does Not Relate to Pain
  94. “Mitochondrial Toolbox” – A Review of Online Resources to Explore Mitochondrial Genomics
  95. Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial
  96. The impact of chronic kidney disease on developed countries from a health economics perspective: A systematic scoping review
  97. Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus
  98. Association of reduced inner retinal thicknesses with chronic kidney disease
  99. Association of soluble ST2 with all-cause and cardiovascular mortality in renal transplant recipients: a single-centre cohort study
  100. Evaluation of long-term intravitreal anti-vascular endothelial growth factor injections on renal function in patients with and without diabetic kidney disease
  101. Comparison of methylation patterns generated from genomic and cell-line derived DNA using the Illumina Infinium MethylationEPIC BeadChip array
  102. Serum xanthophyll carotenoids are associated with estimated glomerular filtration rate in an aged cohort
  103. Awareness, Understanding and Treatment Practices when Managing Cachexia in End‐Stage Kidney Disease
  104. Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen
  105. The Challenges of Chromosome Y Analysis and the Implications for Chronic Kidney Disease
  106. Differential methylation as a diagnostic biomarker of rare renal diseases: a systematic review
  107. Genetic renal disorders
  108. Differential Expression of Urinary Exosomal MicroRNAs miR-21-5p and miR-30b-5p in Individuals with Diabetic Kidney Disease
  109. Identifying Malnutrition in End-stage Renal Disease (ESRD) (P12-037-19)
  110. Genetic Susceptibility to Chronic Kidney Disease – Some More Pieces for the Heritability Puzzle
  111. Genomic Mismatch at LIMS1 Locus and Kidney Allograft Rejection
  112. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial
  113. Genetic associations between genes in the renin-angiotensin-aldosterone system and renal disease: a systematic review and meta-analysis
  114. The impact of donor and recipient common clinical and genetic variation on estimated glomerular filtration rate in a European renal transplant population
  115. Serum amyloid A levels are associated with polymorphic variants in the serum amyloid A 1 and 2 genes
  116. Proteomic and metabolomic approaches in the search for biomarkers in chronic kidney disease
  117. Long-Term Outcomes of Renal Transplant in Recipients With Lower Urinary Tract Dysfunction
  118. Intravenous Iron in Patients Undergoing Maintenance Hemodialysis
  119. Mitochondria and Chronic Kidney Disease: A Molecular Update
  120. Genome-wide association study of diabetic kidney disease highlights biology involved in renal basement membrane collagen
  121. Risk prediction for acute kidney injury in acute medical admissions in the UK
  122. Chronic kidney disease, health-related quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England
  123. Cardiovascular risk in renal transplant recipients
  124. Advance Care Planning With Patients Who Have End-Stage Kidney Disease: A Systematic Realist Review
  125. Validation of differentially methylated microRNAs identified from an epigenome-wide association study; Sanger and next generation sequencing approaches
  126. Genomic approaches in the search for molecular biomarkers in chronic kidney disease
  127. Polygenic risk score as a determinant of risk of non-melanoma skin cancer in a European-descent renal transplant cohort
  128. Quality of life with conservative care compared with assisted peritoneal dialysis and haemodialysis
  129. Healthcare use, costs and quality of life in patients with end-stage kidney disease receiving conservative management: results from a multi-centre observational study (PACKS)
  130. A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes
  131. Dietary patterns and chronic kidney disease: a cross-sectional association in the Irish Nun Eye Study
  132. Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes
  133. Retinal microvascular parameters are not associated with reduced renal function in a study of individuals with type 2 diabetes
  134. Establishing a clinical phenotype for cachexia in end stage kidney disease – study protocol
  135. Long- and short-term outcomes in renal allografts with deceased donors: A large recipient and donor genome-wide association study
  136. Arterial stiffness alone does not explain arteriovenous fistula outcomes
  137. Dietary Patterns and Retinal Vessel Caliber in the Irish Nun Eye Study
  138. Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients
  139. Learning to prescribe intravenous fluids: A scoping review
  140. Estimated Glomerular Filtration Rate is not Associated with Alzheimer’s Disease in a Northern Ireland Cohort
  141. Design and implementation of a custom next generation sequencing panel for selected vitamin D associated genes
  142. Development of next generation sequencing panel for UMOD and association with kidney disease
  143. Clinician views of patient decisional conflict when deciding between dialysis and conservative management: Qualitative findings from the PAlliative Care in chronic Kidney diSease (PACKS) study
  144. High-volume haemofiltration for sepsis in adults
  145. Type 2 Diabetes in Young Females Results in Increased Serum Amyloid A and Changes to Features of High Density Lipoproteins in Both HDL2 and HDL3
  146. Distinguishing Between Cachexia, Sarcopenia and Protein Energy Wasting in End-Stage Renal Disease Patients on Dialysis
  147. The Genetic Landscape of Renal Complications in Type 1 Diabetes
  148. A Rare Cause of Myoclonus
  149. Wnt6 regulates epithelial cell differentiation and is dysregulated in renal fibrosis
  150. Analysis of single nucleotide polymorphisms implicate mTOR signalling in the development of new-onset diabetes after transplantation
  151. Orals
  152. Evidence for three genetic loci involved in both anorexia nervosa risk and variation of body mass index
  153. EAPC2016: Abstracts
  154. Correction
  155. Does the co-existence of acute anterior uveitis and chronic back pain prompt primary care physicians to consider a diagnosis of axial spondyloarthritis?
  156. Arterial Stiffness and Arteriovenous Fistula Failure of Maturation
  157. Preoperative radial artery volume flow is predictive of arteriovenous fistula outcomes
  158. A HuGE Review and Meta-Analyses of Genetic Associations in New Onset Diabetes after Kidney Transplantation
  159. Bioinformatic Evaluation of Transcriptional Regulation of WNT Pathway Genes with reference to Diabetic Nephropathy
  160. Ethical reasoning through simulation: a phenomenological analysis of student experience
  161. Quality of Life and Physical Function in Older Patients on Dialysis: A Comparison of Assisted Peritoneal Dialysis with Hemodialysis
  162. Investigating clinical predictors of arteriovenous fistula functional patency in a European cohort
  163. Arteriovenous fistula outcomes in the elderly
  164. Evaluation of the Retinal Vasculature in Hypertension and Chronic Kidney Disease in an Elderly Population of Irish Nuns
  165. Genetic Evidence for a Causal Role of Obesity in Diabetic Kidney Disease
  166. PAlliative Care in chronic Kidney diSease: the PACKS study—quality of life, decision making, costs and impact on carers in people managed without dialysis
  167. Genetic renal abnormalities
  168. Recipient obesity and outcomes after kidney transplantation: a systematic review and meta-analysis
  169. Retinal microvascular network attenuation in Alzheimer's disease
  170. DEFINING CACHEXIA IN A RENAL POPULATION
  171. Genetics of Diabetic Nephropathy: a Long Road of Discovery
  172. Learning fluid prescription skills: why is it so challenging?
  173. Distinct methylation patterns in genes that affect mitochondrial function are associated with kidney disease in blood-derived DNA from individuals with Type 1 diabetes
  174. Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with Type 1 diabetes
  175. Current tools for prediction of arteriovenous fistula outcomes
  176. Diagnosis and management of hyponatraemia: AGREEing the guidelines
  177. Genetic studies of body mass index yield new insights for obesity biology
  178. New genetic loci link adipose and insulin biology to body fat distribution
  179. Patient survival following arteriovenous fistula formation
  180. Optimizing outcomes in the elderly with end-stage renal disease—live long and prosper
  181. Retinal Vascular Caliber, Iris Color, and Age-Related Macular Degeneration in the Irish Nun Eye Study
  182. Next-generation sequencing of the mitochondrial genome and association with IgA nephropathy in a renal transplant population
  183. SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes
  184. Analysis of data from the ERA-EDTA Registry indicates that conventional treatments for chronic kidney disease do not reduce the need for renal replacement therapy in autosomal dominant polycystic kidney disease
  185. AN APPRAISAL OF END-OF-LIFE CARE IN PERSONS WITH CHRONIC KIDNEY DISEASE DYING IN HOSPITAL WARDS
  186. Genetic and epigenetic factors influencing chronic kidney disease
  187. Factors influencing survival after kidney transplant failure
  188. Genetics and Genomics of Chronic Kidney Disease
  189. Surveillance of Nonmelanoma Skin Cancer Incidence Rates in Kidney Transplant Recipients in Ireland
  190. Preserving Arteriovenous Fistula Outcomes during Surgical Training
  191. β Cell Glucotoxic-Associated Single Nucleotide Polymorphisms in Impaired Glucose Tolerance and New-Onset Diabetes After Transplantation
  192. Treatment of choroidal neovascularisation secondary to membranoproliferative glomerulonephritis type II with intravitreal ranibizumab
  193. Genetic and Epigenetic Risk Factors for Diabetic Kidney Disease
  194. Genome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes
  195. Basic and clinical science posters
  196. Type 1 diabetes and MODY
  197. Using ancestry-informative markers to identify fine structure across 15 populations of European origin
  198. Should women with diabetic nephropathy considering pregnancy continue ACE inhibitor or angiotensin II receptor blocker therapy until pregnancy is confirmed?
  199. A genome-wide association study of anorexia nervosa
  200. New onset diabetes after transplantation: unravelling the pathophysiological process
  201. Polycystic Kidney Disease
  202. Glycated Hemoglobin and Risk of Death in Diabetic Patients Treated With Hemodialysis: A Meta-analysis
  203. Estimated Glomerular Filtration Rate Decline as a Predictor of Dialysis in Kidney Transplant Recipients
  204. Genetics of New-Onset Diabetes after Transplantation
  205. DNA hypermethylation and DNA hypomethylation is present at different loci in chronic kidney disease
  206. Chronic kidney disease and diabetes in the National Health Service: a cross-sectional survey of the UK National Diabetes Audit
  207. Management of hyperkalaemia
  208. Bioinformatic Resources For Diabetic Nephropathy
  209. Chromosome 2q31.1 Associates with ESRD in Women with Type 1 Diabetes
  210. Caveolin-1 Single Nucleotide Polymorphism in Antineutrophil Cytoplasmic Antibody Associated Vasculitis
  211. Haplotype association analysis of genes within the WNT signalling pathways in diabetic nephropathy
  212. Obesity and kidney disease in type 1 and 2 diabetes: an analysis of the National Diabetes Audit
  213. CD2AP is associated with end-stage renal disease in patients with type 1 diabetes
  214. Comprehensive Investigation of the Caveolin 2 Gene: Resequencing and Association for Kidney Transplant Outcomes
  215. Association Analysis of Dyslipidemia-Related Genes in Diabetic Nephropathy
  216. Lipoxins Attenuate Renal Fibrosis by Inducing let-7c and Suppressing TGFβR1
  217. A LITERATURE REVIEW OF END-STAGE RENAL DISEASE AND CACHEXIA: UNDERSTANDING EXPERIENCE TO INFORM EVIDENCE-BASED HEALTHCARE
  218. High-volume haemofiltration for sepsis
  219. TGFβ and CCN2/CTGF mediate actin related gene expression by differential E2F1/CREB activation
  220. Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
  221. Association of Donor and Recipient Calcineurin Inhibitor Pharmacogenomic Variation with Long-Term Allograft Survival
  222. Donor ABCB1 Variant Associates with Increased Risk for Kidney Allograft Failure
  223. New Susceptibility Loci Associated with Kidney Disease in Type 1 Diabetes
  224. Dense fine-mapping study identifies new susceptibility loci for primary biliary cirrhosis
  225. Association of MYH9/APOL1 with chronic kidney disease in a UK population
  226. Epigenetics
  227. Association Testing of Previously Reported Variants in a Large Case-Control Meta-analysis of Diabetic Nephropathy
  228. SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes
  229. Genetic Examination of SETD7 and SUV39H1/H2 Methyltransferases and the Risk of Diabetes Complications in Patients With Type 1 Diabetes
  230. Association analysis of proopiomelanocortin (POMC) haplotypes in type 1 diabetes in a UK population
  231. Novel Susceptibility Locus at 22q11 for Diabetic Nephropathy in Type 1 Diabetes
  232. Association Analysis of Canonical Wnt Signalling Genes in Diabetic Nephropathy
  233. ANCA-associated vasculitis is linked to carriage of the Z allele of  1 antitrypsin and its polymers
  234. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
  235. Genetic renal abnormalities
  236. Elevated soluble cellular adhesion molecules are associated with increased mortality in a prospective cohort of renal transplant recipients
  237. Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis
  238. Patterns of hospitalisation before and following initiation of haemodialysis: a 5 year single centre study
  239. Association analysis of Notch pathway signalling genes in diabetic nephropathy
  240. Managing diabetic nephropathy
  241. The finding of reduced estimated glomerular filtration rate is associated with increased mortality in a large UK population
  242. Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus
  243. Investigation of ACE, ACE2 and AGTR1 genes for association with nephropathy in Type 1 diabetes mellitus
  244. DNA methylation profiling in cell models of diabetic nephropathy
  245. Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial
  246. Advances in the Genetics of Familial Renal Cancer
  247. Association of Caveolin-1 Gene Polymorphism With Kidney Transplant Fibrosis and Allograft Failure
  248. Erythropoietin-Induced Activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK Pathways Promotes Malignant Cell Behavior in a Modified Breast Cancer Cell Line
  249. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer
  250. Resequencing of the CCL5 and CCR5 genes and investigation of variants for association with diabetic nephropathy
  251. A GREM1 Gene Variant Associates with Diabetic Nephropathy
  252. Polymorphisms of the macrophage migration inhibitory factor gene in a UK population with Type 1 diabetes mellitus
  253. Investigation of the association of BMP gene variants with nephropathy in Type 1 diabetes mellitus
  254. Elevated Homocysteine Is a Predictor of All-Cause Mortality in a Prospective Cohort of Renal Transplant Recipients
  255. Evaluation of Five Interleukin Genes for Association with End-Stage Renal Disease in White Europeans
  256. Genetic Polymorphisms in Nitric Oxide Synthase 3 Gene and Implications for Kidney Disease: A Meta-Analysis
  257. A cautionary tale of a man with haemochromatosis, chronic kidney disease and anaemia referred for erythropoietin therapy
  258. Targeted genome-wide investigation identifies novel SNPs associated with diabetic nephropathy
  259. Revascularization versus Medical Therapy for Renal-Artery Stenosis
  260. High-volume haemofiltration for sepsis
  261. A rare haplotype of the vitamin D receptor gene is protective against diabetic nephropathy
  262. The Impact of Admissions for the Management of End-Stage Renal Disease on Hospital Bed Occupancy
  263. Association of microsatellite markers on chromosomes 6q27 region and 10p15 region with end-stage renal disease in a UK renal transplant population
  264. Replication studies based on findings from a genome-wide DNA microsatellite screen in diabetic nephropathy
  265. The changing pattern of adult primary glomerular disease
  266. Chronic kidney disease and bisphosphonate treatment: are prescribing guidelines unnecessarily restrictive?
  267. Comparative analysis of DNA methylation profiles in peripheral blood leukocytes versus lymphoblastoid cell lines
  268. The coronary artery disease SNP, rs4420638, is associated with diabetic nephropathy rather than end-stage renal disease
  269. Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
  270. Response of vulval lichen sclerosus and squamous hyperplasia to photodynamic treatment using sustained topical delivery of aminolevulinic acid from a novel bioadhesive patch system
  271. Elevated Serum Phosphate Predicts Mortality in Renal Transplant Recipients
  272. Genetic analysis of coronary artery disease single-nucleotide polymorphisms in diabetic nephropathy
  273. Annotated chromosome maps for renal disease
  274. Investigation of DNA polymorphisms in SMAD genes for genetic predisposition to diabetic nephropathy in patients with type 1 diabetes mellitus
  275. HLA antigen frequencies and Wegener's granulomatosis
  276. Unravelling the genetic basis of renal diseases; from single gene to multifactorial disorders
  277. Association of Genetic Variants at 3q22 with Nephropathy in Patients with Type 1 Diabetes Mellitus
  278. Early acute kidney injury in Northern Ireland ICUs
  279. Genetics of Diabetic Nephropathy: Are There Clues to the Understanding of Common Kidney Diseases?
  280. The Challenge of Doing What Is Right in Renal Transplantation: Balancing Equity and Utility
  281. The uptake of cervical cancer screening by renal transplant recipients
  282. Genetic association analyses of non-synonymous single nucleotide polymorphisms in diabetic nephropathy
  283. No support for association of protein kinase C, beta 1 (PRKCB1) gene promoter polymorphisms c.-1504C>T and c.-546C>G with diabetic nephropathy in Type 1 diabetes
  284. The evolution of renal transplantation in clinical practice: for better, for worse?
  285. Investigation ofAdducin 2 (beta)DNA polymorphisms in genetic predisposition to diabetic nephropathy in Type 1 diabetes
  286. Heme Oxygenase-1 Gene Promoter Polymorphisms and Outcomes of Clinical Renal Transplantation
  287. Heme Oxygenase 1: Does It Have a Role in Renal Cytoprotection?
  288. Hypokalaemic paralysis precipitated by distal renal tubular acidosis secondary to Sjögren's syndrome
  289. Critiques of Clinical Guidelines in Nephrology: Anaemia
  290. Pathophysiology of anemia and erythrocytosis
  291. Association of functional haem oxygenase-1 gene promoter polymorphism with polycystic kidney disease and IgA nephropathy
  292. The practical implications of using standardized estimation equations in calculating the prevalence of chronic kidney disease
  293. Troponin T is an independent predictor of mortality in renal transplant recipients
  294. Multiple Superoxide Dismutase 1/Splicing Factor Serine Alanine 15 Variants Are Associated With the Development and Progression of Diabetic Nephropathy: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complication...
  295. Decreased Serum Retinol Is Associated with Increased Mortality in Renal Transplant Recipients
  296. In Reply
  297. Association of VEGF-1499C→T polymorphism with diabetic nephropathy in type 1 diabetes mellitus
  298. Genetic renal abnormalities
  299. Gene discovery in diabetic nephropathy
  300. Level of renal function and serum erythropoietin levels independently predict anaemia post-renal transplantation
  301. Association of Functional Heme Oxygenase-1 Gene Promoter Polymorphism with Renal Transplantation Outcomes
  302. Warning Flags for Erythropoiesis-Stimulating Agents and Cancer-Associated Anemia
  303. Reply Orlistat and renal failure
  304. Common polymorphisms of thePAI1gene do not play a major role in the development of diabetic nephropathy in Type 1 diabetes
  305. Resequencing of genes for transforming growth factor β1 (TGFB1) type 1 and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with diabetic nephropathy
  306. Impaired Downregulation Following Erythropoietin Receptor Activation in Non-Small Cell Lung Carcinoma
  307. Are gatekeepers to renal services referring patients equitably?
  308. Association between Haptoglobin Gene Variants and Diabetic Nephropathy: Haptoglobin Polymorphism in Nephropathy Susceptibility
  309. Cost Should Be the Principal Determinant of Choice of Erythropoiesis-Stimulating Agent in Chronic Haemodialysis Patients
  310. Does angiotensin blockade influence graft outcome in renal transplant recipients with IgA nephropathy?
  311. Identifying genes for diabetic nephropathy--current difficulties and future directions
  312. Rapidly progressive renal failure associated with successful pharmacotherapy for obesity
  313. The PAX4 gene variant A1168C is not associated with early onset Type 1 diabetes in a UK population
  314. Cardiac tamponade … a wire too far?
  315. Resequencing of the characterised CTGF gene to identify novel or known variants, and analysis of their association with diabetic nephropathy
  316. A Genome-Wide DNA Microsatellite Association Screen to Identify Chromosomal Regions Harboring Candidate Genes in Diabetic Nephropathy
  317. Induction of Signalling in Non-Erythroid Cells by Pharmacological Levels of Erythropoietin
  318. Late referral for assessment of renal failure
  319. Interleukin 18 promoter polymorphisms are not strongly associated with type I diabetes in a UK population
  320. Cytokine gene polymorphisms in ischaemic heart disease: investigation using family-based tests of association
  321. Role of  -adducin DNA polymorphisms in the genetic predisposition to diabetic nephropathy
  322. Association Between Variation in the Actin-Binding Gene Caldesmon and Diabetic Nephropathy in Type 1 Diabetes
  323. Association of intercellular adhesion molecule-1 gene with type 1 diabetes
  324. Is screening for factor V leiden and prothrombin G20210A mutations in renal transplantation worthwhile? results of a large single-center U.K. study1
  325. Dialysis Clinic: Skin Thickness and Subcutaneous Erythropoietin
  326. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
  327. Correction of anaemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis
  328. The IL12B 3′ untranslated region DNA polymorphism is not associated with early-onset type 1 diabetes
  329. EPO's Alter Ego: Erythropoietin Has Multiple Actions
  330. Novel erythropoiesis-stimulating protein in the management of the anemia of chronic renal failure
  331. A nested primer set targeting the cytomegalovirus glycoprotein B gene
  332. Influence of progressive renal dysfunction in chronic heart failure
  333. AINT/ERIC/TACC: An Expanding Family of Proteins with C-terminal Coiled Coil Domains
  334. Analysis of the association between diabetic nephropathy and polymorphisms in the aldose reductase gene in Type 1 and Type 2 diabetes mellitus
  335. Possible association between CTLA4 DNA polymorphisms and early onset type 1 diabetes in a UK population
  336. The Influence of Transforming Growth Factor-β1 Gene Polymorphisms on the Severity of Gingival Overgrowth Associated With Concomitant Use of Cyclosporin A and a Calcium Channel Blocker
  337. Characterization and localization of expression of an erythropoietin-induced gene, ERIC-1/TACC3, identified in erythroid precursor cells
  338. Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation
  339. Autosomal dominant Alport syndrome caused by a COL4A3 splice site mutation
  340. Is There an Association Between Angiotensin-Converting Enzyme Gene Variants and Chronic Nonproductive Cough?
  341. Reduction in gingival overgrowth associated with conversion from cyclosporin A to tacrolimus
  342. The calcium channel blocker used with cyclosporin has an effect on gingival overgrowth
  343. The Ferroxidase Activity of Caeruloplasmin Is Reduced in Haemodialysis Patients
  344. Allele resolution of HLA-A using oligonucleotide probes in a two-stage typing strategy
  345. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients
  346. Erythropoietin production: evidence for multiple oxygen sensing pathways
  347. Regulation of Erythropoietin Gene Expression Depends on Two Different Oxygen-Sensing Mechanisms
  348. Improved prognosis for congenital nephrotic syndrome of the Finnish type in Irish families
  349. Homocysteine and B-group vitamins in renal transplant patients
  350. MTHFR gene polymorphism and diabetic nephropathy in type 1 diabetes
  351. Risk of developing diabetic nephropathy is not associated with synergism between the angiotensin II (type 1) receptor C1166 allele and poor glycaemic control
  352. HDL composition and HDL antioxidant capacity in patients on regular haemodialysis
  353. Plasma Glutathione Peroxidase Activity Is Reduced in Haemodialysis Patients
  354. AN INTERLUEKIN 1B ALLELE, WHICH CORRELATES WITH A HIGH SECRETOR PHENOTYPE, IS ASSOCIATED WITH DIABETIC NEPHROPATHY
  355. Sequence characterisation and expression of homeobox HOX A7 in the multi-potential erythroleukaemic cell line TF-1
  356. National scientific medical meeting 1997 abstracts
  357. Autosomal dominant Alport syndrome linked to the type IV collage  3 and  4 genes (COL4A3 and COL4A4)
  358. Up-regulation of the endothelial cell adhesion molecule intercellular adhesion molecule-1 (ICAM-1) by autoantibodies in autoimmune vasculitis
  359. Up-regulation of the granulocyte adhesion molecule Mac-1 by autoantibodies in autoimmune vasculitis
  360. A molecular variant of angiotensinogen is associated with diabetic nephropathy in IDDM
  361. A Molecular Variant of Angiotensinogen Is Associated With Diabetic Nephropathy in IDDM
  362. Production and Isolation of the Recombinant N-Lobe of Human Serum Transferrin from the Methylotrophic YeastPichia pastoris
  363. LOCALIZATION OF ERYTHROPOIETIN GENE EXPRESSION IN PROXIMAL RENAL TUBULAR CELLS DETECTED BY DIGOXIGENIN‐LABELLED OLIGONUCLEOTIDE PROBES
  364. LOCALIZATION OF ERYTHROPOIETIN GENE EXPRESSION IN PROXIMAL RENAL TUBULAR CELLS DETECTED BY DIGOXIGENIN-LABELLED OLIGONUCLEOTIDE PROBES
  365. Irish nephrological society
  366. Cytosolic phospholipase A2gene expression in rat mesangial cells is regulated post-transcriptionally
  367. ACE gene typing
  368. Isolation of promoter for cytosolic phospholipase A2 (cPLA2)
  369. Reduced Phospholipase A2 Activity Is Not Accompanied by Reduced Arachidonic Acid Release
  370. Epidermal growth factor and phorbol myristate acetate increase expression of the mRNA for cytosolic phospholipase A2in glomerular mesangial cells
  371. Renal replacement therapy in multiple myeloma and systemic amyloidosis
  372. MicroCorrespondence
  373. Glomerulonephritis associated with antibodies to neutrophil cytoplasm and glomerular basement membrane.
  374. HLA antigen frequencies and Wegener's granulomatosis
  375. Outcome of pregnancy following renal transplantation
  376. Erythropoietin production in kidney tubular cells
  377. Subcutaneous Erythropoietin Therapy and Hypertensive Encephalopathy
  378. The effect of hypobaric hypoxia on misonidazole binding in normal and tumour-bearing mice
  379. Reversal of renal failure in nephritis associated with antibody to glomerular basement membrane.
  380. Assessment of cell‐mediated immunity in a British population using multiple skin test antigens